MiMedx Group, Inc. (MDXG)
$4.70+0.21%Close
SELLRECOVERY · day 115
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $700M
- Beta
- 1.42
- P/E (TTM)
- 117.50
- Short % float
- 7.94%
- Days to cover
- 7.3
- SI change
- -13.0%
- 1W
- +1.95%
- 1M
- -0.42%
- vs SPY 1W
- +2.09%
- vs SPY 1M
- -2.93%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 46
- VALUE
- 6
- GROWTH
- 62
- GARP
- 56
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC1.6%
REV YoY-
ROE2.6%
EPS YoY-
ROA2.2%
GROSS79
OP2
NET2
[VALUATION]
P/E TTM117.50
P/E FWD42.51
SECTOR PE20.48
INDUSTRY PE13.99
P/B3.22
P/FCF-
EV/EBITDA23.24
EV/EBIT-
PEG1.45
FCF YIELD-
RISK
INT COV-
D/E0.69
ALTMAN Z-
CURR RATIO5.33
ND/EBITDA-
BETA1.42
Company news
FAQ
- What is LOPJLB’s current signal on MDXG?
- LOPJLB’s latest quantitative signal on MiMedx Group, Inc. (MDXG) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is MDXG in?
- MiMedx Group, Inc. (MDXG) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does MiMedx Group, Inc. (MDXG) do?
- MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exc…